ArticlePediatric research2026
Research progress and trends of Mycoplasma pneumoniae pneumonia in children: a bibliometric and visualization analysis (1990s to post-COVID-19 era).
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe COVID-19 pandemic has affected the epidemiology of Mycoplasma pneumoniae pneumonia (MPP). This study aimed to provide a comprehensive overview of research trends, challenges, and advancements in pediatric MPP, particularly in the post-COVID-19 era.
methodsA bibliometric analysis of pediatric MPP literature (1992-2025) from the Web of Science was conducted using VOSviewer and CiteSpace.
resultsA total of 2357 relevant articles were published by 11,318 authors from 2714 institutions across 94 countries. Publications increased significantly during and after the COVID-19 pandemic. China and the United States were the most influential countries, while Soochow University and Capital Medical University were the most active institutions. The top 10 co-cited references included four research articles and six review articles. Over the past 34 years, the research focus has shifted from community-acquired pneumonia (CAP) and pediatric pulmonary diseases to MPP. Current research hotspots include epidemiology, diagnostics, macrolide resistance, refractory MPP, and co-infections, with recent citation bursts related to COVID-19.
conclusionThis bibliometric analysis provides a systematic overview of pediatric MPP research from the 1990s to the post-COVID-19 era. It highlights the need for stronger global collaboration and further epidemiological studies to address MPP-related challenges, especially amid evolving infectious threats like COVID-19. IMPACT: This study offers a comprehensive overview of pediatric Mycoplasma pneumoniae pneumonia (MPP) research from 1992 to 2025, revealing critical changes and advances in the field. Detailed analyses of core contributors, thematic evolution, research hotspots and frontiers advance the overall understanding of pediatric MPP. The findings reveal persistent challenges in epidemiology, diagnostics, macrolide resistance, refractory MPP, and co-infections. This study highlights the necessity of strengthening global collaboration and conducting continuous epidemiological surveillance on MPP amid emerging infectious threats such as COVID-19. These results provide valuable insights for addressing clinical challenges and developing novel therapeutic strategies.
Identifiers
42436310What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.